ADAG Adagene Corp: Forward P/S Multiple
Adagene develops shielded tumor antibodies using AI, generating royalties from major partners. Management is focused on the clinical validation of the SAFE-body platform's precision. The forward P/S ratio reflects the market valuation dynamics relative to expected sales, where 14.50 serves as the base parameter value. High scientific authority and B2B sector trust provide the company with stability.
Analytical breakdowns and data insights for company adagene.com (ADAG)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
- financial results and valuation multiples details:
ADAG - Net Profit|Projected Future Earnings Adagene|ADAG - Price to Earnings Multiple|Forward P/E Multiple Adagene Inc.|ADAG - PEG Multiple|EV/EBITDA Multiple ADAG|ADAG - Operating profit before depreciation charges|Earnings per share for the last twelve months Adagene|ADAG - Earnings per one share for the last 12 months|Quarterly EPS earnings growth adagene.com|ADAG - Earnings per share increase in current year|Earnings growth forecast for next year Adagene
- sales and revenue indicators:
Initial company analysis:ADAG (Adagene Corp)
To assess the credit quality of Adagene (ADAG), the analyst compares the business's market value with projected revenue, utilizing the forward P/S trend as an indicator of market expectations regarding future sales. The stability of this valuation is bolstered by the company's investments in energy-efficient laboratories and sustainable chemical disposal, which mitigate regulatory risks and confirm the asset's fundamental attractiveness within the biotechnology sector.
Competitor analysis for Adagene
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|ADMA - Forward P/S Multiple|PTGX: Forward P/S Multiple|Market Cap to Projected Revenue IMVT|KNSA (Kiniksa) - Forward P/S Multiple|Forward P/S Multiple Grifols SA|Forward P/S Multiple ADPT|Celldex Corp (CLDX) - Projected Price to Revenue|Forward P/S Multiple AUPH (Aurinia Pharmaceuticals)|biocryst.com (BCRX) - Market Cap to Future Revenue Ratio|VERA - Price-to-Projected Revenue Ratio|DNTH (Dianthus Therapeutics Inc) - Market Cap to Projected Revenue|PHVS: Forward P/S Multiple|Market Cap to Future Revenue Ratio AbCellera Corp (ABCL)|TRML (Tourmaline Bio, Inc.) - Forward P/S Multiple|Forward P/S Multiple precigen.com|Forward P/S Multiple PHAR|Nektar Therapeutics Inc - Market Cap to Projected Revenue|Forward P/S Multiple UPB (Upstream Bio Corp)|Forward P/S Multiple Zenas Corp ZBIO|Immunome, Inc. - Forward P/S Multiple|Projected Price to Revenue gossamerbio.com (GOSS)|KalVista Pharmaceuticals, Inc. (KALV) - Price-to-Projected Revenue Ratio|Future Price to Revenue SEPN (Septerna, Inc.)|PVLA (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|SVRA: Forward Price to Sales|Forward P/S Multiple RIGL|Forward P/S Multiple anaptysbio.com (ANAB)|Price-to-Projected Revenue Ratio Astria Therapeutics, Inc. ATXS|Forward Price to Sales ENGN|RAPT - Price-to-Projected Revenue Ratio|Aerovate Therapeutics Inc (JBIO) - Forward Price-to-Revenue Multiple|ACRS: Forward P/S Multiple|kyvernatx.com (KYTX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple TLSA|CABA: Forward Price to Sales|Forward P/S Multiple VTYX|Market Cap to Expected Sales Ratio Theratechnologies, Inc|Price-to-Projected Revenue Ratio Avalo Therapeutics, Inc AVTX|ELDN - Forward Price-to-Revenue Multiple|AGEN - Price-to-Projected Revenue Ratio|Climb Bio Inc. (CLYM) - Forward Price-to-Revenue Multiple|ZURA (Zura Bio Limited) - Forward Price-to-Revenue Multiple|aTyr Pharmaceuticals (ATYR) - Forward P/S Multiple|Price-to-Projected Revenue Ratio ImageneBio|Market Cap to Projected Revenue STTK (Shattuck Therapeutics)|Forward P/S Multiple EQ|CNTB - Market Cap to Future Revenue Ratio|Forward P/S Multiple IMUX (Immunic)|Forward P/S Multiple Atara Biotherapeutics, Inc. ATRA|InflaRx GmbH - Forward P/S Multiple|XFOR (x4pharma.com) - Market Cap to Projected Revenue|ACET: Forward P/S Multiple|Celularity (CELU) - Forward P/S Multiple|INMB (INmune Bio Corp) - Forward P/S Multiple|BRNS - Projected Price to Revenue|Forward P/S Multiple KZR|SABS - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Akari Therapeutics Plc AKTX|ENLV: Market Cap to Projected Revenue|Q32 Bio Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio GeoVax Corp|EDSA: Forward P/S Multiple|ibioinc.com (IBIO) - Forward P/S Multiple|CARM (Carisma Therapeutics Inc) - Forward P/S Multiple|Market Cap to Projected Revenue XTLB (XTL Biopharmaceuticals Ltd)|Forward P/S Multiple BOLT|Forward P/S Multiple hcwbiologics.com (HCWB)|Forward P/S Multiple APVO (Aptevo Therapeutics Inc.)|Projected Price to Revenue AIM ImmunoTech, Inc.|ADTX - Price-to-Projected Revenue Ratio|Future Price to Revenue GRI|XRTX: Forward P/S Multiple|Vyome Therapeutics - Forward Price to Sales|REVB (Revelation Biosciences) - Forward P/S Multiple|Forward P/S Multiple indaptusrx.com|Price-to-Projected Revenue Ratio Scinai Immunotherapeutics Ltd. (SCNI)|CALI (calcimedica.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio Affimed N.V. AFMD|ALLK - Forward Price-to-Revenue Multiple|HOOKIPA - Forward P/S Multiple|IGMS - Forward P/S Multiple|ITOS (iTeos Therapeutics, Inc.) - Forward Price-to-Revenue Multiple|Ocean Biomedical Inc - Forward Price to Sales|TCBP (TC BioPharm (Holdings) PLC) - Forward P/S Multiple|Third Harmonic Bio Inc (THRD) - Market Cap to Expected Sales Ratio
